Ian Postlethwaite

Ian Postlethwaite brings over 14 years of biopharma experience and a proven track record of driving revenue growth and funding development programs. He has broad experience in both private and public companies; from start-ups to multi-nationals.

He was previously an Executive Director on the board of Allergy Therapeutics plc. He joined Allergy in April 2002 as Finance Director whilst it was private company, initially performing a financial turnaround and then listing it two years later in 2004 on the AIM of the London Stock Exchange. Revenue increased from £12 to c.£49m over his tenure and he raised £107m through equity issues and €40m through debt finance to fund over 15 clinical studies.

Prior to this he worked for Ellerman Investments (1997-2002), a UK private equity house, undertaking the roles of Chief Executive Officer with AFS, which was one of the largest independent finance houses in the UK, raising over £400m in debt finance, and Finance Director with a number of successful start-up technology companies. Previously he held senior finance positions with Ericsson and Philips Electronics.

He is also a non-executive director and Deputy Chairman of Shoreham Port. He is a Fellow of the Chartered Association of Certified Accountants and has a BSc (Hons) in Geological Sciences from Aston University.

Brian Walker

David Moore

Head of Spin Outs & Investments, QUBIS Ltd. David is Investment Manager with QUBIS Ltd, the early stage investment fund responsible for the commercialisation of technology from The Queen’s University of Belfast.